<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCD</journal-id><journal-title-group><journal-title>World Journal of Cardiovascular Diseases</journal-title></journal-title-group><issn pub-type="epub">2164-5329</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/wjcd.2017.72004</article-id><article-id pub-id-type="publisher-id">WJCD-74322</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Mitral Valve Commissurotomy: Which One between the Three Techniques Gives a Better Long-Team Outcome?
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mahdi</surname><given-names>Aithoussa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Noureddine</surname><given-names>Atmani</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ayoub</surname><given-names>Abetti</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mehdi</surname><given-names>Bamous</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdessamad</surname><given-names>Abdou</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Younes</surname><given-names>Moutakiallah</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Anis</surname><given-names>Seghrouchni</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fouad</surname><given-names>Nya</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Siham</surname><given-names>Bellouize</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohamed</surname><given-names>Drissi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ilyas</surname><given-names>Asfalou</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abdelatif</surname><given-names>Boulahya</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Cardiology, Mohamed V Military Hospital, Mohammed V University, Rabat, Morocco</addr-line></aff><aff id="aff1"><addr-line>Department of Cardiac Surgery, Mohamed V Military Hospital, Mohammed V University, Rabat, Morocco</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>abettiayoub@gmail.com(AA)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>02</month><year>2017</year></pub-date><volume>07</volume><issue>02</issue><fpage>37</fpage><lpage>45</lpage><history><date date-type="received"><day>October</day>	<month>25,</month>	<year>2016</year></date><date date-type="rev-recd"><day>Accepted:</day>	<month>February</month>	<year>21,</year>	</date><date date-type="accepted"><day>February</day>	<month>24,</month>	<year>2017</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   Objective
   : we sought to compare long-term results of three techniques: CMC, OMC and PMC in patients with rheumatic mitral stenosis. 
   Patients and 
   Method: Between January 1994 and December 2015, 183 patients underwent mitral valve surgery for rheumatic mitral restenosis. All patients were investigated by echocardiography-Doppler performed by a senior cardiologist. The patients were divided into 3 groups: patients who have previously closed mitral commissurotomy (CMC n = 101), patients with previously open mitral commissurotomy (OMC n = 28) and those treated by Balloon mitral valvuloplasty (PMC = 54). 
   Results: The three groups were comparable in term of major demographic data. Mitral restenosis occurred precociously in groups treated by PMC (7 &#177; 4 years), followed by group with OMC 11.4 &#177; 4 years and CMC group but it occurred later CMC 16.8 &#177; 7.8 years (p &lt; 0.01). No statistical difference was found in perioperative and postoperative data. 
   Conclusion: CMC produces better long-term outcome than OMC and PMC. However, it would be premature to conclude to its superiority. 
  
 
</p></abstract><kwd-group><kwd>Rheumatic Mitral Stenosis</kwd><kwd> Closed Mitral Commissurtomy</kwd><kwd> Open Mitral Commissurotomy</kwd><kwd> Balloon Mitral Valvuloplasty</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Rheumatic mitral stenosis (RMS) is a frequent cause of valve disease in developing countries. Its prevalence is at least 10 times higher than in western countries [<xref ref-type="bibr" rid="scirp.74322-ref1">1</xref>] .</p><p>Treatment of RMS has dramatically changed during the last few decades. Depending upon the severity of the disease and the socio-economic level, the treat- ment modality varies and the choice may be either conservative technique or mitral valve replacement procedure.</p><p>There are three conservative measures to treat RMS: closed mitral commissurotomy (CMC), open mitral commissurotomy (OMC) or percutaneous mitral commissurotomy (PMC). It is estimated that about 10% to 30% of patients have developed restenosis 5 - 10 years after initial successful surgical commissurotomy [<xref ref-type="bibr" rid="scirp.74322-ref2">2</xref>] .</p><p>There is a paucity of data comparing long-term results of three conservative techniques. Many questions are still open about which technique allows the excellent long-term outcome and avoids precocious mitral restenosis. This retro- spective study was designed to compare the long-term results of the three conser- vative procedures.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>Among 1535 Consecutive patients who underwent mitral valve surgery at our institution between January 1994 and December 2015, we identified 183 patients (11.9%) who had previously received mitral commissurotomy.</p><p>Patients are divided into three groups: Patients who had closed mitral commissurotomy (CMC, n = 101), patients with previous open commissurotomy (OMC, n = 28) and patients who underwent percutaneous mitral commissurotomy (PMC, n = 54).</p><p>All patients were discussed at heart-team by both the cardiologist and the cardiac surgeons.</p><p>All patients were investigated by 2 dimensional and color Doppler echocardiography performed by a senior cardiologist before surgery.</p><p>The mitral valve area (MVA) was calculated from the Doppler study using the pressure half-time method and by planimetry using the parasternal short axis, and the continuous wave Doppler technique was used to calculate the mitral gradient and systolic pulmonary artery pressure (SPAP). Left ventricular dimension and function and left atrium (LA) diameter were measured as recommended by the American society of Echocardiography [<xref ref-type="bibr" rid="scirp.74322-ref3">3</xref>] . Color Doppler flow imaging was performed for diagnosis and quantification of mitral regurgitation (MR).</p><p>The study included symptomatic patients with mitral restenosis, with MVA ≤ 1.5 cm<sup>2</sup>, isolated MRS or with ≤grade II MR. Were excluded from the study, patients with MR &gt;grade II and those with evidence of coronary artery disease.</p><p>Clinical data including, NYHA functional class, comorbidities, echocardiogra- phic data and surgical data are reported.</p><sec id="s2_1"><title>2.1. Surgical Protocol</title><p>Patients were operated on under general anesthesia and cardiopulmonary bypass (CPB). In redo cardiac surgery, redo sternotomy was performed carefully. Limiting mediastinal dissection to only those structures for cannulation and exposure may reduce mortality and risk of cardiac injury. After initiation of CPB, myocardial protection was maintainted by anterograde intermittent infusion of cold crystalloid cardioplegia before 2000, and cold blood cardioplegia was used for all patients after 2000.</p><p>The judgment criteria of long term result were the interval between the initial mitral commissurotomy and mitral restenosis.</p></sec><sec id="s2_2"><title>2.2. Definitions of Complications</title><p>Complications were defined in accordance with the published guidelines for reporting valve related morbidity and mortality after cardiac valve surgery [<xref ref-type="bibr" rid="scirp.74322-ref4">4</xref>] .</p></sec><sec id="s2_3"><title>2.3. Statistical Analysis</title><p>Statistical analysis was performed with SPSS (Statistical Package for social sci- ence: SPSS Chicago, IL 19.0).</p><p>Data were reported as the meant SD or median with IQ.</p></sec></sec><sec id="s3"><title>3. Results</title><p>As shown in <xref ref-type="table" rid="table1">Table 1</xref>, the three groups were comparable in terms of major demographic data. The patients in the three groups were young and there were more female than male. Women’s were predominantly corresponding to 71% of the patients in this study.</p><p>All patients were symptomatic with more than 60% being in NYHA functional class III-IV. Incidence of preoperative atrial fibrillation was higher in patients with previous CMC (72.3%) vs. 61% in patients with PMC and 57% in those with OMC (p = 0.19). But the low incidence of preoperative cerebrovacular accident was found in CMC group.</p><p>Echocardiographic data showed that patients with mitral restenosis after OMC had large left atrium diameter than other groups (OMC: 58 &#177; 12.5 mm vs. CMC: 53.9 &#177; 8.3 vs. 52 &#177; 9.2 mm in PMC with p = 0.032).</p><p>The mean MVA was also statistically different in the three groups: CMC: 1.05 &#177; 0.3 cm&#178; vs. 1.05 &#177; 0.2 cm&#178; in PMC group and 1.26 &#177; 0.4 cm&#178; OMC group (p = 0.01).</p><p>But not differences were found between groups in regard to other echographic parameters (LV diameters, LV ejection function, pulmonary artery pressure). Mitral restenosis occurred precociously in patients who underwent PMC than other groups: mean time interval between initial mitral commissurotomy and restenosis was: 7 &#177; 4 years in PMC group vs. 11.4 &#177; 4 years in OMC group and 16.8 &#177; 7.8 years in CMC group (p = 0.001).</p><p>Comorbidities expressed by Euroscore were frequent in patients with CMC or OMC than those treated by PMC (p = 0.001).</p><p>The 30_day mortality was similar between all groups (p = 0.98). There was no significant difference in the postoperative complications. But patients with CMC and those with OMC required more RBC transfusion compared with group treated previously by BMC (CMC: 41.4% vs. OMC: 32.1% and PMC: 13.5%, p = 0.002) (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Left atrial thrombosis was found only in 2 cases in group with OMC.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Patient’s baseline characteristics</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variable</th><th align="center" valign="middle" >CMC (n = 101)</th><th align="center" valign="middle" >OMC (n = 28)</th><th align="center" valign="middle" >PMC (n = 54)</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >Age (years)</td><td align="center" valign="middle" >43.5 &#177; 9 7</td><td align="center" valign="middle" >38.7 &#177; 10 4</td><td align="center" valign="middle" >431 &#177; 9.8</td><td align="center" valign="middle" >0.071</td></tr><tr><td align="center" valign="middle" >Sex F/M</td><td align="center" valign="middle" >73/28</td><td align="center" valign="middle" >16/12</td><td align="center" valign="middle" >44/10</td><td align="center" valign="middle" >0.063</td></tr><tr><td align="center" valign="middle" >BMI kg/m<sup>2</sup></td><td align="center" valign="middle" >24.2 &#177; 3.9</td><td align="center" valign="middle" >23.3 &#177; 3</td><td align="center" valign="middle" >23.9 &#177; 3</td><td align="center" valign="middle" >0.48</td></tr><tr><td align="center" valign="middle" >NYHA class III - IV</td><td align="center" valign="middle" >59 (58.4%)</td><td align="center" valign="middle" >18 (64.3%)</td><td align="center" valign="middle" >34 (63%)</td><td align="center" valign="middle" >0.78</td></tr><tr><td align="center" valign="middle" >CTI</td><td align="center" valign="middle" >0.57 &#177; 0.06</td><td align="center" valign="middle" >0.58 &#177; 0.08</td><td align="center" valign="middle" >0.56 &#177; 0.05</td><td align="center" valign="middle" >0.31</td></tr><tr><td align="center" valign="middle" >AF n (%)</td><td align="center" valign="middle" >73 (72.3%)</td><td align="center" valign="middle" >16 (57%)</td><td align="center" valign="middle" >33 (61%)</td><td align="center" valign="middle" >0.19</td></tr><tr><td align="center" valign="middle" >Preop CVA n (%)</td><td align="center" valign="middle" >2 (2%)</td><td align="center" valign="middle" >3 (10.7%)</td><td align="center" valign="middle" >3 (5.6%)</td><td align="center" valign="middle" >0.11</td></tr><tr><td align="center" valign="middle" >Renal dysfunction</td><td align="center" valign="middle" >3 (3%)</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" >2 (3.7%)</td><td align="center" valign="middle" >0.6</td></tr><tr><td align="center" valign="middle" >CPOD (%)</td><td align="center" valign="middle" >6 (5.9%)</td><td align="center" valign="middle" >1 (3.6%)</td><td align="center" valign="middle" >1 (1.9%)</td><td align="center" valign="middle" >0.48</td></tr><tr><td align="center" valign="middle" >LA diameter mm</td><td align="center" valign="middle" >53.9 &#177; 8,3</td><td align="center" valign="middle" >58 &#177; 12.5</td><td align="center" valign="middle" >52 &#177; 9.2</td><td align="center" valign="middle" >0.032</td></tr><tr><td align="center" valign="middle" >LV ESD mm</td><td align="center" valign="middle" >33.9 &#177; 6</td><td align="center" valign="middle" >34.5 &#177; 7.5</td><td align="center" valign="middle" >34.4 &#177; 7.5</td><td align="center" valign="middle" >0.89</td></tr><tr><td align="center" valign="middle" >LV EDD mm</td><td align="center" valign="middle" >50.5 &#177; 7.2</td><td align="center" valign="middle" >53.2 &#177; 7.6</td><td align="center" valign="middle" >50.7 &#177; 8.8</td><td align="center" valign="middle" >0.3</td></tr><tr><td align="center" valign="middle" >RF (%)</td><td align="center" valign="middle" >32 &#177; 6.9</td><td align="center" valign="middle" >32.7 &#177; 6.8</td><td align="center" valign="middle" >31.9 &#177; 7.8</td><td align="center" valign="middle" >0.89</td></tr><tr><td align="center" valign="middle" >LV EF (%)</td><td align="center" valign="middle" >60.8 &#177; 9.4</td><td align="center" valign="middle" >61.5 &#177; 9.1</td><td align="center" valign="middle" >60 &#177; 9</td><td align="center" valign="middle" >0.77</td></tr><tr><td align="center" valign="middle" >SPAP mmhg</td><td align="center" valign="middle" >50.8 &#177; 20.5</td><td align="center" valign="middle" >53.4 &#177; 20.8</td><td align="center" valign="middle" >51.6 &#177; 15.7</td><td align="center" valign="middle" >0.83</td></tr><tr><td align="center" valign="middle" >MVA (cm<sup>2</sup>)</td><td align="center" valign="middle" >1.05 &#177; 0.3</td><td align="center" valign="middle" >1.26 &#177; 0.4</td><td align="center" valign="middle" >1.05 &#177; 0.2</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >Mitral valve gradient (mmhg)</td><td align="center" valign="middle" >10.8 &#177; 4.3</td><td align="center" valign="middle" >9.3 &#177; 2.6</td><td align="center" valign="middle" >12.2 &#177; 4</td><td align="center" valign="middle" >0.2</td></tr><tr><td align="center" valign="middle" >Time years Follow-up period</td><td align="center" valign="middle" >16.8 &#177; 7.8</td><td align="center" valign="middle" >11.4 &#177; 4</td><td align="center" valign="middle" >7 &#177; 4</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >LV EF &lt;40%</td><td align="center" valign="middle" >3 (3%)</td><td align="center" valign="middle" >1 (3.6%)</td><td align="center" valign="middle" >2 (3.7%)</td><td align="center" valign="middle" >0.96</td></tr><tr><td align="center" valign="middle" >Euroscore</td><td align="center" valign="middle" >4.84 &#177; 2</td><td align="center" valign="middle" >4.96 &#177; 2</td><td align="center" valign="middle" >1.73 &#177; 2.2</td><td align="center" valign="middle" >&lt;0.01</td></tr></tbody></table></table-wrap><p>AF: atrial fibrillation, BMI: body mass index, CPOD: Chronic obstructive pulmonary disease, CTI: cardiothoracic index, LA: left atrium, LVEDD: left ventricular end diastolic diameter, LVEF: left ventricular ejection fraction, LVESD: left ventricular end systolic diameter, MVA: mitral valve area, RF: racourcissement fraction, SPAP: systolic pulmonary artery pressure.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Early surgical results</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variable</th><th align="center" valign="middle" >CMC (n = 101)</th><th align="center" valign="middle" >OMC (n = 28)</th><th align="center" valign="middle" >PMC (n = 54)</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >No elective surgery n (%)</td><td align="center" valign="middle" >1 (1%)</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" >1 (1.9%)</td><td align="center" valign="middle" >0.73</td></tr><tr><td align="center" valign="middle" >Mean CPB time (min)</td><td align="center" valign="middle" >102.5 &#177; 41</td><td align="center" valign="middle" >114.6 &#177; 43.8</td><td align="center" valign="middle" >109 &#177; 48</td><td align="center" valign="middle" >0.37</td></tr><tr><td align="center" valign="middle" >Mean Aortic Cross Clamp time (min)</td><td align="center" valign="middle" >69.4 &#177; 34.2</td><td align="center" valign="middle" >78.9 &#177; 32</td><td align="center" valign="middle" >74.3 &#177; 42</td><td align="center" valign="middle" >0.42</td></tr><tr><td align="center" valign="middle" >Mean surgical procedure time (min)</td><td align="center" valign="middle" >205.6 &#177; 56.3</td><td align="center" valign="middle" >234 &#177; 68</td><td align="center" valign="middle" >204.8 &#177; 51.3</td><td align="center" valign="middle" >0.054</td></tr><tr><td align="center" valign="middle" >Mean MV support-time (H)</td><td align="center" valign="middle" >9 (6 - 18)</td><td align="center" valign="middle" >10 (6 - 18)</td><td align="center" valign="middle" >5 (4 - 7)</td><td align="center" valign="middle" >0,19</td></tr><tr><td align="center" valign="middle" >ICU stay</td><td align="center" valign="middle" >24 (22 - 48)</td><td align="center" valign="middle" >44 (24 - 60)</td><td align="center" valign="middle" >38 (24 - 48)</td><td align="center" valign="middle" >0.67</td></tr><tr><td align="center" valign="middle" >Postoperative stay</td><td align="center" valign="middle" >12.8 &#177; 9</td><td align="center" valign="middle" >14.9 &#177; 9.6</td><td align="center" valign="middle" >11.6 &#177; 4.6</td><td align="center" valign="middle" >0.27</td></tr><tr><td align="center" valign="middle" >LOS n (%)</td><td align="center" valign="middle" >11 (10.9 %)</td><td align="center" valign="middle" >4 (14.3%)</td><td align="center" valign="middle" >3 (5.6%)</td><td align="center" valign="middle" >0.39</td></tr><tr><td align="center" valign="middle" >Reexploration for bleeding n (%)</td><td align="center" valign="middle" >4 (4%)</td><td align="center" valign="middle" >1 (3.6%)</td><td align="center" valign="middle" >2 (3.8%)</td><td align="center" valign="middle" >0.99</td></tr><tr><td align="center" valign="middle" >Postoperative RI n (%)</td><td align="center" valign="middle" >4 (4%)</td><td align="center" valign="middle" >2 (7.2%)</td><td align="center" valign="middle" >4 (7.4%)</td><td align="center" valign="middle" >0.62</td></tr><tr><td align="center" valign="middle" >RBC transfusion n (%)</td><td align="center" valign="middle" >41 (41.4%)</td><td align="center" valign="middle" >9 (32.1%)</td><td align="center" valign="middle" >7 (13.5%)</td><td align="center" valign="middle" >&lt;0.01</td></tr><tr><td align="center" valign="middle" >In hospital mortality rate n (%)</td><td align="center" valign="middle" >8 (7.9%)</td><td align="center" valign="middle" >2 (7.1%)</td><td align="center" valign="middle" >4 (7.4%)</td><td align="center" valign="middle" >0.98</td></tr><tr><td align="center" valign="middle" >MOF (%)</td><td align="center" valign="middle" >7 (7.1%)</td><td align="center" valign="middle" >2 (7.1%)</td><td align="center" valign="middle" >2 (3.9%)</td><td align="center" valign="middle" >0.73</td></tr></tbody></table></table-wrap><p>CPB: cardio pulmonary bypass, ICU: intensive care unit, LOS: low out pout syndrome, RBC: red blood cell, MOF: multivisceral organe failure.</p></sec><sec id="s4"><title>4. Discussion</title><p>Our study compared long-tem results obtained after mitral commissurotomy for RMS performed with three techniques: CMC, OMC and PMC. The main criteria were mitral restenosis. The study showed that mitral restenosis occurred precociously in patients treated by PMC 7 &#177; 4 years followed by those treated by OMC 11.4 &#177; 4 years, However mitral restenosis occurred later in patients who had previous CMC 16.8 &#177; 7.8 years (p = 0.001).</p><p>Rheumatic mitral stenosis (RMS) is a frequent cause of valve disease in developing countries [<xref ref-type="bibr" rid="scirp.74322-ref5">5</xref>] . Its prevalence is at least 10 times higher than in developed countries [<xref ref-type="bibr" rid="scirp.74322-ref1">1</xref>] . Treatment of RMS has dramatically changed during the last few decades. Depending upon the severity of the disease, the treatment modality varies and the choice may be either conservative techniques: Closed mitral commissurotomy (CMC), open mitral commissurotomy (OMC), percutaneous mitral commissurotomy (PMC) or straight way mitral valve replacement (MVR).In most cardiac centers, in developing countries CMC has been the favored technique for the treatment of RMS for several reasons. Became the affected poor patients cannot afford the cost of replacement by mechanical or bio-prosthetic valve and CMC remains an alternative saving therapy for them. CMC was widely done with good results in major cities as early as the 1960. However some disadvantages of CMC are real and must be appreciated. Since 1970, numerous surgeons have abandoned CMC in such patients and do an OMC. This technique, allowing direct inspection and treatment of the valve and its subvalvular apparatus, gradually replaced closed technique. But CMC in expert hand is a safe alternative to OMC and PMC [<xref ref-type="bibr" rid="scirp.74322-ref6">6</xref>] . In 1984, the introduction of PMC once again modified the therapeutic strategy of RMS [<xref ref-type="bibr" rid="scirp.74322-ref7">7</xref>] . PMC not only avoids all the complications associated with a surgical operation, open or closed, but also is cost effective [<xref ref-type="bibr" rid="scirp.74322-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref9">9</xref>] . Many comparative studies [<xref ref-type="bibr" rid="scirp.74322-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref11">11</xref>] were performed between series of patients treated with different techniques trying to establish the superiority of the latest technique over the others. Until today, there are still controversies about the long term results when comparing the three conservative techniques. It is known that conservative procedure is not a definitive therapy for mitral stenos is but rather a temporary palliative measure.</p><p>Also, it is interesting to remember that mitral valve disease is a continuously progressive disease. Often, repeat intervention is necessary after a certain period of time. Few studies are performed on randomized series and had a relatively short follow-up [<xref ref-type="bibr" rid="scirp.74322-ref12">12</xref>] . There is one randomized and prospective study comparing the long term (7 years) clinical and echocardiographic follow-up of the three conservative procedures [<xref ref-type="bibr" rid="scirp.74322-ref13">13</xref>] . This study concluded that PMC and OMC produce excellent and comparable hemodynamic improvement and associated with a lower rate of restenosis and need for re-intervention when compared to CMC.</p><p>Despite its retrospective design, our study was performed in order to compare to three conservative techniques. We found that the three groups were homogenous for preoperative clinical variables echocardiographic data.</p><p>Prolonged follow-up revealed that the incidence of restenosis was as high as 30% - 40% after 10 years, which resulted in an increasing number of patients needing reoperation. According to the large group case reports in china, Liu et al reported that the average time interval between the initial mitral commissurotomy and the reoperation was 13 &#177; 6.8 years. Our results showed that recurrence of mitral stenosis occurred later after CMC compared to reports published in the literature 16.8 &#177; 7.8 years. Older studies found that reoperation is required due to restenosis is usually after about 10 years [<xref ref-type="bibr" rid="scirp.74322-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref16">16</xref>] . With the progress in CPB and myocardial protection, CMC gradually gave way to open mitral commissurotomy. Choudhary et al. found that outcome of OMC is better than CMC and it provides excellent early and long term results in a selected group of patients [<xref ref-type="bibr" rid="scirp.74322-ref17">17</xref>] .</p><p>Since mitral balloon valvuloplasty (PMC) was introduced in 1984 by Inoue [<xref ref-type="bibr" rid="scirp.74322-ref7">7</xref>] and its widespread application, it’s an effective treatment option for significant RMS. The efficacy of BMV has been well documented and accompanied by similar outcome as other methods [<xref ref-type="bibr" rid="scirp.74322-ref18">18</xref>] . (Today a similar area can be obtained after PMC) [<xref ref-type="bibr" rid="scirp.74322-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref19">19</xref>] . The immediate and long term results of BMV are similar to those of closed and open surgical commissurotomy in comparable groups of patients [<xref ref-type="bibr" rid="scirp.74322-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref21">21</xref>] . Moreover, some authors have shown PMC to be comparable or superior to CMC [<xref ref-type="bibr" rid="scirp.74322-ref22">22</xref>] . After PMC, approximately 7% to 21% of patients develop recurrent heart failure due to mitral restenosis [<xref ref-type="bibr" rid="scirp.74322-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref24">24</xref>] . In our study, mitral restenosis occurred more frequently in patients who had PMC (7 &#177; 4 years). In one study, symptomatic mitral restenosis occurred 11 &#177; 4 years after PMC [<xref ref-type="bibr" rid="scirp.74322-ref25">25</xref>] .</p><p>In the literature were have observed different restenosis frequency among the studies, ranging from 3 to 7 years. In recent report [<xref ref-type="bibr" rid="scirp.74322-ref26">26</xref>] , mitral restenosis occurred in 44.1% of patients in a mean 49 &#177; 31 months follow-up. In the other hand, not all patients were found to have an optimal mitral valve area, and it suggested that the mechanism of successful PMC may be more complex than reported previously [<xref ref-type="bibr" rid="scirp.74322-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref28">28</xref>] .</p><p>Wang et al. [<xref ref-type="bibr" rid="scirp.74322-ref29">29</xref>] observed gradual and progressive loss of the mitral valve area, after PMC and absence of correlation Between MVA and restenosis, suggesting that it is a part of an ongoing biological process rather than mechanical or retraction process.</p><p>Numerous studies identified some factors that favor a more successful outcome as: young age, satisfactory valvular anatomy, echocardiographic score ≤8, presence of sinus rhythm, absence of mitral regurgitation before the procedure, and absence of surgical mitral commissurotomy before the procedure [<xref ref-type="bibr" rid="scirp.74322-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.74322-ref31">31</xref>] .</p>Study Limitations<p>This study has several limits inherent to its retrospective design. Despite restenosis of mitral area occurred later after CMC, it is difficult to conclude its superiority than other techniques.</p><p>The three techniques were performed in different centers by different practitioners; hence, it is difficult to establish direct comparison among the three tech- niques. The lack of data concerning mitral valve anatomy before BMV may not help to separate favorable cases (score &gt;8).</p></sec><sec id="s5"><title>5. Conclusion</title><p>This study showed that CMC and OMC produce excellent long-term results and have low rate mitral restenosis. However, it would be premature to come to a definitive conclusion inherent to study limitations.</p></sec><sec id="s6"><title>Cite this paper</title><p>Aithoussa, M., Atmani, N., Abetti, A., Bamous, M., Abdou, A., Moutakiallah, Y., Seghrouchni, A., Nya, F., Bellouize, S., Drissi, M., Asfalou, I. and Boulahya, A. (2017) Mitral Valve Commissurotomy: Which One between the Three Techniques Gives a Better Long-Team Out- come? World Journal of Cardiovascular Di- seases, 7, 37-45. https://doi.org/10.4236/wjcd.2017.72004</p></sec></body><back><ref-list><title>References</title><ref id="scirp.74322-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Hildick-Smith, D.J., Taylor, G.J. and Shapiro, L.M. (2000) Inoue Balloon Mitral Valvuloplasty: Long-Term Clinical and Echocardiographic Follow-Up of a Predominantly Unfavourable Population. European Heart Journal, 21, 1690-1697. https://doi.org/10.1053/euhj.2000.2241</mixed-citation></ref><ref id="scirp.74322-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Palacios, I.F., Tuzcu, M.E., Weyman, A.E., Newell, J.B. and Block, P.C. (1995) Clinical Follow-Up of Patients Undergoing Percutaneous Mitral Balloon Valvotomy. Circulation, 91, 671-676. https://doi.org/10.1161/01.CIR.91.3.671</mixed-citation></ref><ref id="scirp.74322-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Wang, A., Krasuski, R.A., Warner, J.J., et al. (2002) Serial Echocardiographic Evaluation of Restenosis after Successful Percutaneous Mitral Commissurotomy. Journal of the American College of Cardiology, 39, 328-334. https://doi.org/10.1016/S0735-1097(01)01726-0</mixed-citation></ref><ref id="scirp.74322-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hasan-Ali, H., Shams-Eddin, H., Abd-Elsayed, A.A. and Maghraby, M.H. (2007) Echocardiographic Assessment of Mitral Valve Morphology after Percutaneous Transvenous Mitral Commissurotomy (PTMC). Cardiovascular Ultrasound, 5, 48.</mixed-citation></ref><ref id="scirp.74322-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Fatkin, D., Roy, P., Morgan, J.J. and Feneley, M.P. (1993) Percutaneous Balloon Mitralvalvotomy with the Inoue Single-Balloon Catheter: Commissural Morphology as a Determinant of Outcome. Journal of the American College of Cardiology, 21, 390-397. https://doi.org/10.1016/0735-1097(93)90680-Y</mixed-citation></ref><ref id="scirp.74322-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Borges, I.P., Peixoto, E.C.S., Peixoto, R.T.S., de Oliveira, P.S., Netto, M.S., Labrunie, P., Labrunie, M., Peixoto, R.T.S. and de Amorim, V.R. (2005) Percutaneous Mitral Balloon Valvotomy. Long-Term Outcome and Assessment of Risk Factors for Death and Major Events. ArquivosBrasileiros de Cardiologia, 84, 397-404.</mixed-citation></ref><ref id="scirp.74322-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">EidFawzy, M., Hassan, W., Shoukri, M., Al Sanei, A., Hamadanchi, A., El Dali, A. and Al Amri, M. (2005) Immediate and Long-Term Results of Mitral Balloon Valvotomy for Restenosis Following Previous Surgical or Balloon Mitral Commissurotomy. American Journal of Cardiology, 96, 971-975. https://doi.org/10.1016/j.amjcard.2005.05.055</mixed-citation></ref><ref id="scirp.74322-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Iung, B., Cormier, B., Ducimetiere, P., et al. (1996) Functional Results 5 Years after Successful Percutaneous Mitral Commissurotomy in a Series of 528 Patients and Analysis of Predictive Factors. Journal of the American College of Cardiology, 27, 407-414. https://doi.org/10.1016/0735-1097(95)00481-5</mixed-citation></ref><ref id="scirp.74322-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cohen, D.J., Kuntz, R.E., Gordon, S.P.F., et al. (1992) Predictors of Long-Term Outcome after Percutaneous Mitral Valvuloplasty. The New England Journal of Medicine, 327, 1329-1335. https://doi.org/10.1056/NEJM199211053271901</mixed-citation></ref><ref id="scirp.74322-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Essop, R., Rothlisberger, C., Dullabh, A. and Sareli, P. (1995) Can the Long Term Outcomes of Percutaneous Balloon Mitral Valvotomy and Surgical Commissurotomy be Expected to Be Similar? The Journal of Heart Valve Disease, 4, 446-452.</mixed-citation></ref><ref id="scirp.74322-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Pathan, A.Z., Mahdi, N.A., Leon, M.N., Lopez-Cuellar, J., Simosa, H., Block, P.C., Harrell, L. and Palacios, I.F. (1999) Is Redo Percutaneous Mitral Balloon Valvuloplasty (PMV) Indicated in Patients with Post-PMV Mitral Restenosis? Journal of the American College of Cardiology, 34, 49-54.</mixed-citation></ref><ref id="scirp.74322-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Reyes, V.P., Raju, B.S., Wynne, J., et al. (1994) Percutaneous Balloon Valvuloplasty Compared with Open Surgical Commissurotomy for Mitral Stenosis. The New England Journal of Medicine, 331, 961-967. https://doi.org/10.1056/NEJM199410133311501</mixed-citation></ref><ref id="scirp.74322-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Turi, Z.G., Reyes, V.P., Raju, B.S., et al. (1991) Percutaneous Balloon versus Surgical Closed Commissurotomy for Mitral Stenosis: A Prospective, Randomized Trial. Circulation, 83, 1179-1185. https://doi.org/10.1161/01.CIR.83.4.1179</mixed-citation></ref><ref id="scirp.74322-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">De Souza, J.A.M., Martinez Jr, E.E., Ambrose, J.A., Alves, C.M.R., Born, D., Buffolo, E. and Carvalho, A.C.C. (2001) Percutaneous Balloon Mitral Valvuloplasty in Comparison with Open Mitral Valve Commissurotomy for Mitral Stenosis during Pregnancy. Journal of the American College of Cardiology, 37, 900-903. https://doi.org/10.1016/S0735-1097(00)01184-0</mixed-citation></ref><ref id="scirp.74322-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Choudhary, S.K., Dhareshwar, J., Govil, A., Airan, B. and Kumar, A.S. (2003) Open Mitral Commissurotomy in the Current Era: Indications, Technique, and Results. The Annals of Thoracic Surgery, 75, 41-46. https://doi.org/10.1016/S0003-4975(02)04276-5</mixed-citation></ref><ref id="scirp.74322-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">John, S., Bashi, W., Jairaj, P.S., et al. (1983) Closed Mitral Valvotomy: Early Results and Long-Term Follow-Up of 3724 Consecutive Patients. Circulation, 68, 891-896. https://doi.org/10.1161/01.CIR.68.5.891</mixed-citation></ref><ref id="scirp.74322-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Fraser, K. and Sugden, B.A. (1977) Second Closed Mitral Valvotomy for Recurrent Mitral Stenosis. Thorax, 32, 759-762.</mixed-citation></ref><ref id="scirp.74322-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Nathaniels, E.K., Moncure, A.C. and Scannell, J.G. (1970) A Fifteen-Year Follow-Up Study of Closed Mitral Valvuloplasty. The Annals of Thoracic Surgery, 10, 27-36. https://doi.org/10.1016/S0003-4975(10)65561-0</mixed-citation></ref><ref id="scirp.74322-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Farhat, M.B., Ayari, M., Maatouk, F., Betbout, F., Gamra, H., Jarrar, M., Tiss, M., Hammami, S., Thaalbi, R. and Addad, F. (1998) Percutaneous Balloon versus Surgical Closed and Open Mitral Commissurotomy Seven-Year Follow-Up Results of a Randomized Trial. American Heart Association, 97, 245-250. https://doi.org/10.1161/01.cir.97.3.245</mixed-citation></ref><ref id="scirp.74322-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Arora, R., Nair, M., Kalra, G.S., Nigam, M. and Khalilullah, M. (1993) Immediate and Long-Term Results of Balloon and Surgical Closed Mitral Valvotomy: A Randomized Comparative Study. American Heart Journal, 125, 1091-1094.</mixed-citation></ref><ref id="scirp.74322-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Raju, B.S., Turi, Z. and Raju, R. (1993) Three and One-Half Year Follow-Up of a Randomized Trial Comparing Percutaneous Balloon and Surgical Closed Mitral Commissurotomy. Journal of the American College of Cardiology, 21, 818.</mixed-citation></ref><ref id="scirp.74322-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Hickey, M.S.J., Blackstone, E.H., Kirklin, J.W. and Dean, L.S. (1991) Outcome Probabilities and Life History after Surgical Mitral Commissurotomy: Implications for Ballon Commissurotomy. Journal of the American College of Cardiology, 17, 29-42.</mixed-citation></ref><ref id="scirp.74322-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Cheng, T.O. (2003) No More Comparative Studies of Percutaneous Balloon Valvuloplasty versus Open Surgical Commissurotomy for Mitral Stenosis. Cardiology, 99, 216. https://doi.org/10.1159/000071253</mixed-citation></ref><ref id="scirp.74322-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Rifaie, O., Abdel-Dayem, M.K., Ramzy, A., Ezz-El-Din, H., El-Ziady, G., El-Itriby, A., El-Sayed, H., Wagdy, H., Awadallah, H. and Nammas, W. (2009) Percutaneous Mitral Valvotomy versus Closed Surgical Commissurotomy. Up to 15 Years of Follow-Up of a Prospective Randomized Study. Journal of Cardiology, 53, 28-34. https://doi.org/10.1016/j.jjcc.2008.08.003</mixed-citation></ref><ref id="scirp.74322-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Inoue, K., Owaki, T., Nakamura, T., Kitamura, F. and Miyamoto, N. (1984) Clinical Application of Transvenous Mitral Commissurotomy by a New Balloncatheter. The Journal of Thoracic and Cardiovascular Surgery, 87, 394-402.</mixed-citation></ref><ref id="scirp.74322-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Ates, A., Unlu, Y., Yekeler, I., Erkut, B., Balci, A.Y., Ozyazicioglu, A. and Kocak, H. (2005) Role of Closed Mitral Commissurotomy for Mitral Stenosis: Mid-and Long-Term Surgical Outcome of 36 Patients. The Heart Surgery Forum, 8, E55-E59.</mixed-citation></ref><ref id="scirp.74322-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Farhat, M.B., Ayari, M., Maatouk, F., et al. (1998) Percutaneous Balloon Versussurgical Closed and Open Mitral Commissurotomy: Seven-Year Follow-Up Results of a Randomized Trial. Circulation, 97, 245-250. https://doi.org/10.1161/01.CIR.97.3.245</mixed-citation></ref><ref id="scirp.74322-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Edmunds, L.H., Clark, L.H., Miller, D.C. and Weisel, R.D. (1988) Guidelines for Reporting Morbidity and Mortality after Cardiac Valvular Operations. The Journal of Thoracic and Cardiovascular Surgery, 86, 351-353.</mixed-citation></ref><ref id="scirp.74322-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Schiller, N., Shah, P., Crawford, M., De Maria, A., Devereux, R., Feigenbaum, H., Gutgesell, H., Reichek, N., Sahn, D., Schnittger, I. and Tajik, A., American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms (1989) Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography. Journal of the American Society of Echocardiography, 2, 358-367.https://doi.org/10.1016/S0894-7317(89)80014-8</mixed-citation></ref><ref id="scirp.74322-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">John, S., Perianayagam, W.J., Abraham, K.A., et al. (1978) Restenosis of Mitral Valve: Surgical Consideration and Result of Operation. The Annals of Thoracic Surgery, 25, 316-321. https://doi.org/10.1016/S0003-4975(10)63548-5</mixed-citation></ref><ref id="scirp.74322-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Enio, E., Guerios, R.B., et al. (2005) Mitral Stenosis and Percutaneousmitralvalvuloplasty (Part 1). The Journal of Invasivecardiology, 17, 382-386.</mixed-citation></ref></ref-list></back></article>